

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
You can purchase shares of NewAmsterdam Pharma Co (NASDAQ:NAMS) through any online brokerage.
Other companies in NewAmsterdam Pharma Co’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
NewAmsterdam Pharma Co has a consensus price target of $46.00.
The stock price for NewAmsterdam Pharma Co (NASDAQ: NAMS) is $20.65 last updated October 28, 2026 at 11:39 AM EDT.
There are no upcoming dividends for NewAmsterdam Pharma Co.
NewAmsterdam Pharma Co does not have any upcoming earnings scheduled.
There is no upcoming split for NewAmsterdam Pharma Co.
NewAmsterdam Pharma Co is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.